Leukemia drug trial pulled before it even started

NCT ID NCT06522373

Terminated Disease control Sponsor: M.D. Anderson Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This was a very early (Phase 1) study to test the safety of a new drug called MT-0169 in people with certain types of acute leukemia (AML or T-ALL) that had come back or not responded to treatment. The drug was given through a vein. However, the study was withdrawn before any patients were enrolled, so no results are available.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

MT-0169 (given by vein)

What this could lead to

If it works, this could point toward a new treatment option for certain types of acute leukemia that have not responded to standard therapy.

What could go wrong

This trial was withdrawn before enrolling any participants, so no data on safety or effectiveness exist. It is very early-stage research, and many such drugs never prove safe or effective.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute biphenotypic leukemia acute myeloid leukemia leukemia mixed phenotype acute leukemia T-cell acute lymphoblastic leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LEUKEMIA